Cytokine-Based Cancer Immunotherapies Summit

March 24 - 25, 2021 - KS US

Hanson Wade

This is the primary industry platform dedicated to providing you insight into the latest clinical results and stimulating discussions around how to take cytokine-based immunotherapy combinations forward. The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a 'hot' tumor, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapies approaches. The virtual Cytokine-based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients. Join us and leading experts from Roche, CytomX, Philogen, Bristol-Myers Squibb, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose, determining the mechanisms of action and hear the latest data coming out of the clinic. Running digitally March 24-25, 2021. Group discounts and early booking rates are available. Please visit the website for full pricing information.

More Information